Adaptive Biotechnologies (ADPT) awards stock to Chief Commercial Officer Bobulsky

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky received two awards of common stock on March 4, 2026. She acquired 59,375 shares in one grant and 62,500 shares in another, both at a reported price of $0.00 per share, increasing her directly held stake.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer, MRD

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		59,375	A	$0	406,613	D
Common Stock	03/04/2026		A		62,500	A	$0	469,113	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Adaptive Biotechnologies (ADPT) report in Susan Bobulsky’s latest Form 4?

Adaptive Biotechnologies reported that Chief Commercial Officer, MRD, Susan Bobulsky received two stock awards. On March 4, 2026, she acquired 59,375 and 62,500 shares of common stock, both reported at a price of $0.00 per share, as direct ownership.

How many Adaptive Biotechnologies shares did Susan Bobulsky acquire in this Form 4 filing?

Susan Bobulsky acquired two separate grants of Adaptive Biotechnologies common stock. One award was for 59,375 shares and the other for 62,500 shares, both recorded on March 4, 2026, and reported as directly owned with a per-share transaction price of $0.00.

What was the transaction code used in Susan Bobulsky’s Adaptive Biotechnologies Form 4?

The transactions were reported with code “A,” indicating a grant, award, or other acquisition. Both entries cover non-derivative common stock awards to Susan Bobulsky and are categorized as acquisitions rather than open-market purchases or sales, reflecting equity-based compensation.

Did Susan Bobulsky buy or sell Adaptive Biotechnologies (ADPT) stock on the open market?

The Form 4 shows no open-market buys or sells by Susan Bobulsky. Instead, she received two non-derivative common stock awards coded as “A,” meaning grants or other acquisitions, each reported at a transaction price of $0.00 per share as part of her compensation.

How did Susan Bobulsky’s direct ownership in Adaptive Biotechnologies change after the stock awards?

After one of the March 4, 2026 awards, her direct holdings were reported as 406,613 shares. Following the second award, direct ownership was listed as 469,113 shares, indicating both grants increased her directly held common stock position in Adaptive Biotechnologies.

What role does Susan Bobulsky hold at Adaptive Biotechnologies in this Form 4?

In this Form 4, Susan Bobulsky is identified as an officer of Adaptive Biotechnologies, serving as Chief Commercial Officer, MRD. The reported transactions describe stock awards of common shares granted to her in that executive capacity, all classified as directly owned.